home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

6th Annual Drug Development Congress 2014

 
  January 06, 2014  
     
 
Oxford Global, Geneva, Switzerland
2 & 3 June 2014


Agenda

Day 1: Predictive Science
Stem cell technology for effective predictive modeling
Immunogenicity prediction and mitigation
Predictive biomarkers: development and validation
IVIVCS: bridging the gap between in vitro and in vivo
Safety prediction: novel biomarker technology, genetic variation studies
Predictive science in co-medication research
Exploratory toxicology and mechanism based toxicity testing
Predictive challenges: complex biologics and multi-target action
-
Day 2: Translational Medicine
The role of imaging technology in translational medicine
Harmonising ADMET strategy in discovery and development
Integrating toxicology practices throughout the pipeline
New tools for translational medicine: novel immunoassays, resistance biomarkers, toxicogenomic applications
PK/PD – improving decision making from candidate selection to clinical trial
Quantitative science: the building block of translational medicine?

 Please contact Danielle Dalby on d.dalby@oxfordglobal.co.uk for a copy of the full agenda. 

 
 
Organized by: Oxford Global
Invited Speakers:
  • Joerg Bluemel
    Director Biologics Safety Assessment, Translational Sciences, MedImmune
  • Roberta Bursi
    Senior Director Global Biometrics, Head of Pharmacometrics, Grünenthal
  • Donna Dambach
    Director, Director, Small Molecule & Investigative Toxicology, Genentech
  • Hugues Dolgos
    Senior Director, Global Early Development, Translational Medicine Strategy Implementation Leader, Merck Serono
  • Manfred Kansy
    Head Science and Technology Strategy in Non-Clinical Safety, Roche
  • Stephan Kirchner
    Head Discovery Genotoxicity and In Vitro Phototoxicity, Roche
  • Thierry Lave
    Head DMPK Modeling and Simulation, Roche
  • Philip M. Arlen
    President & CEO, Precision Biologics
  • Magnus ord
    Global Section Director Safety Science, AstraZeneca
  • Vito Sasseville
    Preclinical Safety TA head Ophthalmology/ID/NIDU; Head, Discovery and Investigative Pathology, US, Novartis

Please contact Danielle Dalby for more speaker updates.

 
Deadline for Abstracts: N/A
 
Registration: Registration is now open. Please contact Danielle Dalby on d.dalby@oxfordglobal.co.uk for information on attendance and prices.
E-mail: d.dalby@oxfordglobal.co.uk
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.